Skip to content
Lower risk Drug recall · FDA · Published February 20, 2020

Teva Mesalamine Tablets Recall: Failed Dissolution Testing Risk

Teva Pharmaceuticals USA recalls 1.2g Mesalamine Delayed-Release Tablets due to failed dissolution testing. This may affect medication effectiveness. Check NDC 0591-2245-2: 120-count bottle, Rx only, manufactured by Actavis Laboratories.

🇺🇸 FDA recall #D-0862-2020DrugTeva Pharmaceuticals USA ›
Take action

Contact the company

Recalling firmTeva Pharmaceuticals USA400 Interpace Pkwy · Parsippany, NJ 07054-1120
✎ GovInfoNow plain-language explainer

Teva Pharmaceuticals USA is recalling 1.2 gram Mesalamine Delayed-Release Tablets (120-count bottles) because they failed dissolution testing. This could mean the medication doesn't work properly as intended. Read more at govinfonow.com/recall/37370-teva-mesalamine-tablets-recall-failed-dissolution-testing-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/37370-teva-mesalamine-tablets-recall-failed-dissolution-testing-risk · Updated October 5, 2026 · FDA enforcement record: FDA #D-0862-2020

Cite this page

“Teva Mesalamine Tablets Recall: Failed Dissolution Testing Risk.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/37370-teva-mesalamine-tablets-recall-failed-dissolution-testing-risk. Based on FDA recall #D-0862-2020 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0862-2020%22&limit=1).

The Food and Drug Administration announced on Feb. 20, 2020, that Teva Pharmaceuticals USA voluntarily recalled Mesalamine Delayed-Release Tablets due to failed dissolution specifications. The agency classified the recall as Class II.

How to tell if you have it

  • Brand: Teva Pharmaceuticals USA
  • Product: Mesalamine Delayed-Release Tablets, USP, 1.2 gram, 120-count bottle
  • NDC: 0591-2245-22
  • Lot #: 1342500A
  • Expiration Date: 10/2020
  • Manufacturer: Actavis Laboratories FL, Inc.
  • Distributor: Actavis Pharma, Inc.

The hazard

The recall addresses low out-of-specification dissolution results observed during stability testing. The FDA stated that these failed dissolution specifications constitute the hazard for this product.

Context

GovInfoNow's records show Teva Pharmaceuticals USA has 97 other recalls on record since Oct. 11, 2013. Other recent recalls of similar products include Teva Doxylamine Succinate Tablets Recall (Jan. 18, 2022), Teva Tretinoin Capsules 10mg Recall (Jan. 10, 2022), and Teva Mimvey 1mg/0.5mg Tablets Recalled Due to Mislabeling (Jan. 7, 2022). Additional recent recalls include Teva Metoprolol Succinate Tablets Recall (Jan. 29, 2026), Teva Metoprolol Succinate Extended-Release Tablets Recall (Jan. 29, 2026), and Teva Recalls Metoprolol Succinate 50 mg Due to Dissolution Failure (Jan. 29, 2026).

How to tell if you have this one

Check for the 120-count bottle labeled 'Mesalamine Delayed-Release Tablets, USP, 1.2 gram'. The NDC code is 0591-2245-22. The lot number is 1342500A, expiring 10/2020.

  • Brand
    Teva Pharmaceuticals USA
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Medication Details

    Look for the NDC code 0591-2245-22 on the bottle label to confirm it's the recalled product.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA.” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 8 months after the firm started it.

1. Firm started the recall: Feb 20, 202012. FDA classified it Class II: Mar 2, 202023. Published in FDA’s Enforcement Report: Mar 11, 202034. FDA terminated the recall: Oct 6, 202042020
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

✎ GovInfoNow

Questions people ask

Is this medication dangerous?

The recall is due to failed dissolution testing, which may affect medication effectiveness, but it does not pose a safety risk like injury or death.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0862-2020 (February 20, 2020) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0862-2020 to see it in context.
  • Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA